Literature DB >> 11751422

Mechanisms of tolerance to DNA damaging therapeutic drugs.

P Karran1.   

Abstract

The cytotoxic effect of many anticancer drugs relies on their ability to damage DNA. Drug resistance can be associated with the ability to remove potentially lethal DNA lesions. DNA damage tolerance offers an alternative route to resistance. In a drug-tolerant cell, persistent DNA damage has become uncoupled from cell death. Tolerance to some DNA damaging drugs is accompanied by inactivation of the cell's DNA mismatch repair pathway. This is widely acknowledged as the mechanism underlying resistance to methylating agents and to 6-thioguanine which produce structurally similar types of DNA damage. Defects in mismatch repair are also associated with resistance to numerous drugs that produce a wide variety of structurally diverse DNA lesions. Here I consider possible mechanisms by which mismatch repair might influence drug resistance and the extent to which loss of mismatch repair might be considered to confer a multidrug resistance phenotype.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11751422     DOI: 10.1093/carcin/22.12.1931

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  77 in total

1.  Genetic lesions during progression of hereditary non-polypous colorectal cancer.

Authors:  T A Shtam; O A Vostryukhina; A V Gulyaev; K M Pozharissky; V A Lantsov
Journal:  Dokl Biochem Biophys       Date:  2004 Mar-Apr       Impact factor: 0.788

Review 2.  Mismatch repair defects and Lynch syndrome: The role of the basic scientist in the battle against cancer.

Authors:  Christopher D Heinen
Journal:  DNA Repair (Amst)       Date:  2015-12-02

3.  Mismatch repair proteins are activators of toxic responses to chromium-DNA damage.

Authors:  Elizabeth Peterson-Roth; Mindy Reynolds; George Quievryn; Anatoly Zhitkovich
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

4.  ATR kinase activation mediated by MutSalpha and MutLalpha in response to cytotoxic O6-methylguanine adducts.

Authors:  Ken-ichi Yoshioka; Yoshiko Yoshioka; Peggy Hsieh
Journal:  Mol Cell       Date:  2006-05-19       Impact factor: 17.970

Review 5.  Involvement of mismatch repair in transcription-coupled nucleotide excision repair.

Authors:  Katsutoshi Kobayashi; Peter Karran; Shinya Oda; Katsuhiko Yanaga
Journal:  Hum Cell       Date:  2005-09       Impact factor: 4.174

Review 6.  What is wrong with Fanconi anemia cells?

Authors:  Sharon B Cantor; Robert M Brosh
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

7.  Nuclear reorganization of DNA mismatch repair proteins in response to DNA damage.

Authors:  Adam S Mastrocola; Christopher D Heinen
Journal:  DNA Repair (Amst)       Date:  2009-12-08

8.  Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.

Authors:  Gaspar J Kitange; Brett L Carlson; Mark A Schroeder; Patrick T Grogan; Jeff D Lamont; Paul A Decker; Wenting Wu; C David James; Jann N Sarkaria
Journal:  Neuro Oncol       Date:  2008-10-24       Impact factor: 12.300

9.  Disruption of a mitochondrial MutS DNA repair enzyme homologue confers drug resistance in the parasite Toxoplasma gondii.

Authors:  Erin M Garrison; Gustavo Arrizabalaga
Journal:  Mol Microbiol       Date:  2009-03-04       Impact factor: 3.501

Review 10.  DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets.

Authors:  Long Shan Li; Julio C Morales; Martina Veigl; David Sedwick; Sheldon Greer; Mark Meyers; Mark Wagner; Richard Fishel; David A Boothman
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.